In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
Resistance to antimalarial drugs represents a major obstacle for controlling malaria in
endemic countries, so that most sub-Saharan countries have changed their antimalarial drug
policy to the new Artemisinin Containing Therapies. Burkina Faso has changed its policy for
uncomplicated malaria to Artemether-Lumefantrine (AL) and Artesunate-Amodiaquine (AQ+AS), but
there are still little available data on safety and efficacy of these treatments in Burkina
Faso; both treatments have shown to be efficacious, but AL seems to have higher occurrence of
recurrent malaria infections during a 28-day follow up period. Thus, this study aims at
comparing the safety and efficacy of AL and AS-AQ (42-day follow-up), AND also at comparing
their in vitro sensitivity, in patients with recurrent infection, with the results obtained
in vivo.